Big pharma is constantly looking for new ways to control its multi-billion dollar budgets and speed up processes across R&D and commercial divisions. How tightly managers have been able to manage these targets has been a key internal metric. But what if one of these huge corporations were to abandon that core competency of controlling costs, and simply did away with budgets altogether?
This is exactly the radical approach Roche has taken in its commercial division, and three years in, the company...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?